Scholar Rock (SRRK) Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 SMA

Go back to Scholar Rock (SRRK) Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 SMA
(NASDAQ: SRRK) Delayed: 41.49 -0.47 (1.12%)
Previous Close $41.96    52 Week High $ 
Open $41.58    52 Week Low $ 
Day High $41.95    P/E N/A 
Day Low $40.76    EPS $ 
Volume 1,207,203